H.Res. 685
IntroducedExpressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.
Plain-language analysis
Not yet analyzed.
A plain-language breakdown — including any hidden or off-intent provisions and whether the bill was fast-tracked — is generated separately by AI, and any passage it quotes is checked against the bill text before it can be shown. It will appear here once ready. Until then, the verbatim text below and the official source are the record.
Full text of the bill
Official source on Congress.gov ↗[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H. Res. 685 Introduced in House (IH)]
<DOC>
119th CONGRESS 1st Session H. RES. 685
Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 9, 2025
Mrs. Cammack (for herself, Ms. Kamlager-Dove, Mrs. Kim, Ms. Pettersen, Mrs. Hinson, Ms. Adams, Mrs. Cherfilus-McCormick, and Mr. Landsman) submitted the following resolution; which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
RESOLUTION
Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.
Whereas antiphospholipid syndrome (APS) is a condition in which the immune system of an individual mistakenly produces antibodies that increase the risk of blood clots; Whereas APS can increase the risk of miscarriages, stillbirths, and pregnancy complications; Whereas professional medical associations and guideline-setting bodies do not recommend testing for APS as a standard part of prenatal screening; Whereas professional medical associations and guideline-setting bodies recommend testing for APS only if a woman has an unexplained fetal loss after 10 weeks or 3 or more unexplained embryonic losses (miscarriages); Whereas APS is responsible for about 15 percent of recurrent pregnancy losses; Whereas the total number of miscarriages caused by APS is unknown because it is not tested as part of normal prenatal screening; Whereas APS can be detected by a blood test and treated by blood thinners; and Whereas testing for APS during normal prenatal screening can save babies and reduce grief for women and families: Now, therefore, be it Resolved, That the House of Representatives--
(1) supports testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening; and
(2) calls upon professional medical associations and guideline-setting bodies to update their recommendations to include testing for APS as a standard part of prenatal screening. <all>